AutoGenomics granted United States patent for Multi-Patient Array (MPA) technology
Vista, CA -- AutoGenomics, Inc., a leader in providing automated molecular testing solutions to clinical reference laboratories, announced today that it has been granted United States patent for Multi-Patient Array (MPA) technology, increasing its issued patent portfolio to nine.
AutoGenomics’ proprietary MPA technology enables its INFINITI® systems to process multiple samples on a single BioFilmChip® microarray. “This differentiating technology creates increased efficiencies for AutoGenomics’ customers by lowering their operating costs and increasing their throughput, leading to improved laboratory capacity, improved equipment utilization and improved economics”, said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.
Assays utilizing AutoGenomics’ MPA technology can process 2 (Duplex), 4 (QUAD), 6 (HEX) or 8 (OCTA) discrete samples on a single BioFilmChip® microarray. AutoGenomics’ multiplexing technology, combined with its MPA technology, allows its INFINITI® systems to simultaneously detect multiple biomarkers across multiple genes on multiple samples on the same BioFilmChip® microarray.
AutoGenomics currently offers more than 25 assays which incorporate the MPA including:
1. INFINITI® CYP450 2D6-Duplex Assay – Identifies 16 mutations in Cytochrome P450 2D6 gene (including deletions and duplications) in 2 discrete samples simultaneously.
2. INFINITI® Factors Plus QUAD – Identifies 5 mutations in Factor II, Factor V-Leiden and
MTHFR genes in 4 discrete samples simultaneously.
3. INFINITI® HPV-HR HEX Assay - Identifies 14 High Risk Genotypes of Human Papillomavirus Virus (HPV) in 6 discrete samples simultaneously.
4. INFINITI® MTBC-O Assay – Identifies Mycobacterium tuberculosis complex in 8 discrete samples simultaneously.
The above mentioned tests are for research use only.
AutoGenomics, Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer. With the discovery of genes and their link to various disease states, the AutoGenomics’ platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com.
President and Chief Executive Officer
(760) 477-2248 ext. 306